Phase
Condition
Blood Clots
Venous Thromboembolism
Thromboembolism
Treatment
N/AClinical Study ID
Ages 3-12 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Pediatric patients aged 3 months to less than 12 years at the time of Pradaxa Pellets initiation
Written informed consent from parents/care givers and patient assent if ageappropriate
Initiation of Pradaxa Pellets administration either as initial or subsequenttherapy:
Treatment of VTE
Treatment to reduce the risk of recurrence of VTE
Exclusion
Exclusion Criteria:
Participation in any randomized clinical trial or use of investigational product,participation in any other observational study is not an exclusion
Any contraindications to Pradaxa Pellets according to the US PrescribingInformation.
Previous participation in this study.
Study Design
Connect with a study center
University of California, San Diego
La Jolla, California 92093
United StatesSite Not Available
Rady Children's Hospital
San Diego, California 92123
United StatesSite Not Available
Yale University School of Medicine
New Haven, Connecticut 06519
United StatesSite Not Available
Johns Hopkins All Children's Hospital
Saint Petersburg, Florida 33701
United StatesSite Not Available
Indiana Hemophilia & Thrombrosis Center
Indianapolis, Indiana 46260
United StatesSite Not Available
Cincinnati Children's Hospital
Cincinnati, Ohio 45229
United StatesSite Not Available
Dayton Children's Hospital
Dayton, Ohio 45404
United StatesSite Not Available
MUSC (Medical university of South Carolina)
Charleston, South Carolina 29425
United StatesSite Not Available
Vanderbilt University
Nashville, Tennessee 37232
United StatesSite Not Available
Dell Children's Ascension
Austin, Texas 78723
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.